CERo Therapeutics Holdings, Inc. (CERO)
OQB · Healthcare · Biotechnology
$0.01
+9.00%
Closing price as of 2026-09-11 · Source: TEK2day Finance
Key Metrics
Market Cap
$780,777.81
Shares Outstanding
71.6M
Exchange
OQB
Currency
USD
About CERo Therapeutics Holdings, Inc.
CERo Therapeutics Holdings, Inc., an immunotherapy company, engages in the development of engineered T cell therapeutics for the treatment of cancer. The company's lead development candidate is CER-1236, an autologous T cell therapy candidate for the treatment of hematologic malignancies and solid tumors. The company was incorporated in 2021 and is based in South San Francisco, California.
Quarterly Financials
| Metric | 2025-09-30 | 2025-12-31 | 2026-03-31 | 2026-06-30 |
|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Income | (4.4M) | (4.4M) | (4.8M) | (3.8M) |
| Net Income | (4.9M) | (4.5M) | (5.9M) | (1.0M) |
| Diluted EPS | $-9.10 | N/A | $-0.20 | $-0.70 |
Annual Financials
| Metric | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2025-12-31 |
|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Income | (11.6M) | (12.0M) | (7.7M) | (19.3M) |
| Net Income | (10.6M) | (11.8M) | (7.3M) | (19.9M) |
| Diluted EPS | $-2,345.98 | $-2,610.71 | $-1,416.55 | $-22.58 |